Adjunctive type 2 diabetes drug approved

The American Food and Drug Administration has approved a new type 2 diabetes drug to be used in conjunction with metformin, sulfonylureas or insulin .
Welchol, manufactured by Daiichi Sankyo Inc. is the first medication that is approved to reduce both glucose levels and LDL cholesterol levels. Some 40 per cent of type 2 diabetics also suffer from high levels of LDL, so Welchol treats both chronic conditions simultaneously.
Clinically proven data indicates that Welchol could lower haemoglobin A1c and LDL levels amongst patients struggling to control their condition with metformin.
Ronald Goldberg MD, professor of medicine in the division of diabetes and metabolism at the University of Miami Miller School of Medicine was reported as commenting:
“Cardiovascular risk factors are of great concern because patients with type 2 diabetes have a significantly increased risk of developing cardiovascular disease .”